ONOO– and ClO– Responsive Organic Nanoparticles for Specific in Vivo Image-Guided Photodynamic Bacterial Ablation

2018 ◽  
Vol 30 (11) ◽  
pp. 3867-3873 ◽  
Author(s):  
Wenbo Wu ◽  
Duo Mao ◽  
Xiaolei Cai ◽  
Yukun Duan ◽  
Fang Hu ◽  
...  
2019 ◽  
Vol 6 (2) ◽  
pp. 311-317 ◽  
Author(s):  
Xiaolei Cai ◽  
Aishwarya Bandla ◽  
Chan Kim Chuan ◽  
Gayathiri Magarajah ◽  
Lun-De Liao ◽  
...  

Dual-targeted organic nanoparticles efficiently target the margin of glioblastoma and successfully suppress the tumour growth through photothermal therapy.


Molecules ◽  
2021 ◽  
Vol 26 (14) ◽  
pp. 4127
Author(s):  
Aline de Cristo Soares Alves ◽  
Franciele Aline Bruinsmann ◽  
Silvia Stanisçuaski Guterres ◽  
Adriana Raffin Pohlmann

Bevacizumab (BCZ) is a recombinant humanized monoclonal antibody against the vascular endothelial growth factor, which is involved in the angiogenesis process. Pathologic angiogenesis is observed in several diseases including ophthalmic disorders and cancer. The multiple administrations of BCZ can cause adverse effects. In this way, the development of controlled release systems for BCZ delivery can promote the modification of drug pharmacokinetics and, consequently, decrease the dose, toxicity, and cost due to improved efficacy. This review highlights BCZ formulated in organic nanoparticles providing an overview of the physicochemical characterization and in vitro and in vivo biological evaluations. Moreover, the main advantages and limitations of the different approaches are discussed. Despite difficulties in working with antibodies, those nanocarriers provided advantages in BCZ protection against degradation guaranteeing bioactivity maintenance.


2009 ◽  
Vol 36 (6Part1) ◽  
pp. 2206-2214 ◽  
Author(s):  
Angelo Piermattei ◽  
Savino Cilla ◽  
Luca Grimaldi ◽  
Domenico Sabatino ◽  
Andrea Fidanzio ◽  
...  

2007 ◽  
Vol 67 (1) ◽  
pp. 288-295 ◽  
Author(s):  
Hansjoerg Wertz ◽  
Judit Boda-Heggemann ◽  
Cornelia Walter ◽  
Barbara Dobler ◽  
Sabine Mai ◽  
...  

Author(s):  
Seungsoo Kim ◽  
Yun-sheng Chen ◽  
Geoffrey P. Luke ◽  
Stanislav Y. Emelianov

PLoS ONE ◽  
2018 ◽  
Vol 13 (7) ◽  
pp. e0200471 ◽  
Author(s):  
Erik N. K. Cressman ◽  
Chunxiao Guo ◽  
Niloofar Karbasian
Keyword(s):  

2019 ◽  
Vol 46 (11) ◽  
pp. 5134-5143 ◽  
Author(s):  
Sharath K. Bhagavatula ◽  
Kunj Upadhyaya ◽  
Brendyn J. Miller ◽  
Patrick Bursch ◽  
Alex Lammers ◽  
...  

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Hui Zhou ◽  
Xiaodong Zeng ◽  
Anguo Li ◽  
Wenyi Zhou ◽  
Lin Tang ◽  
...  

AbstractNIR-II fluorophores have shown great promise for biomedical applications with superior in vivo optical properties. To date, few small-molecule NIR-II fluorophores have been discovered with donor-acceptor-donor (D-A-D) or symmetrical structures, and upconversion-mitochondria-targeted NIR-II dyes have not been reported. Herein, we report development of D-A type thiopyrylium-based NIR-II fluorophores with frequency upconversion luminescence (FUCL) at ~580 nm upon excitation at ~850 nm. H4-PEG-PT can not only quickly and effectively image mitochondria in live or fixed osteosarcoma cells with subcellular resolution at 1 nM, but also efficiently convert optical energy into heat, achieving mitochondria-targeted photothermal cancer therapy without ROS effects. H4-PEG-PT has been further evaluated in vivo and exhibited strong tumor uptake, specific NIR-II signals with high spatial and temporal resolution, and remarkable NIR-II image-guided photothermal therapy. This report presents the first D-A type thiopyrylium NIR-II theranostics for synchronous upconversion-mitochondria-targeted cell imaging, in vivo NIR-II osteosarcoma imaging and excellent photothermal efficiency.


2012 ◽  
Author(s):  
Hui Wang ◽  
Wei Kang ◽  
Thomas Carrigan ◽  
Austin Bishop ◽  
Noah Rosenthal ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document